-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
At the beginning of the year 2022, big pharmaceutical companies began to non-stop throwing out heavy cooperation
My past was in a small town of less than 20,000 people.
My memories grew like corrugated grass on those low roofs, as well as the slate-paved streets and the jutting out.
Households, a river running through the town, and of course small alleys jutting out from both sides of the street like branches
When I first came to Beijing, high-rise buildings were being built everywhere in Beijing, roads were being built everywhere, Beijing was like a huge construction site, and the shouts of construction workers and the roar of machines continued day and night
.
.
" This sentence made me excited because I didn't know what it would be like to walk on the streets of Beijing in autumn
This is because the Kaza in Beijing does not affect my inner peace
Through this new cooperation, Huadong Medicine will introduce a variety of ADC innovative products
My past was in a small town of less than 20,000 people.
My memories grew like corrugated grass on those low roofs, as well as the slate-paved streets and the jutting out.
Households, a river running through the town, and of course small alleys jutting out from both sides of the street like branches
When I first came to Beijing, high-rise buildings were being built everywhere in Beijing, roads were being built everywhere, Beijing was like a huge construction site, and the shouts of construction workers and the roar of machines continued day and night
.
.
" This sentence made me excited because I didn't know what it would be like to walk on the streets of Beijing in autumn
The coordinated development of anti-infection, respiratory system and other fields” has changed
.
By cooperating with Biositu, we will develop fully human antibody drugs targeting the targets jointly selected by both parties, and rapidly advance the drug research and development of the selected targets .
In cooperation with Jingtai Technology, the two parties will jointly develop new small molecule drugs for difficult targets for the treatment of malignant tumors .
In addition to R&D cooperation and commercialization cooperation, Chia Tai Tianqing and Yiyi Bio have reached a strategic cooperation in China on F-627 (US trade name Ryzneuta).
F-627 is based on Fc fusion protein technology and expressed by CHO cells.
rhG-CSF Dimer for the prevention and treatment of neutropenia in tumor patients during chemotherapy .
Yiyi Bio will receive up to 210 million yuan in down payments and milestone payments, as well as double-digit tiered royalties on net sales .
F-627 is an international multi-center clinical phase III drug and is currently undergoing BLA review by the US FDA .
In 2021, Chia Tai Tianqing invested 2.
74 billion yuan in R&D and obtained 13 new product registration approvals .
According to data from Minet.
com, Chia Tai Tianqing Pharmaceutical has 66 new drugs (excluding new indications for new drugs that have been listed) that are in the clinical application stage and above, of which 52 are Category 1 new drugs .
Among them, 20 biological drugs are in the approved clinical stage and above, and 9 of them are in the phase III clinical stage and above .
At the end of January, Chia Tai Tianqing Pharmaceutical's adalimumab injection was approved for marketing, which is the first approved biosimilar drug of Chia Tai Tianqing .
Currently, CP Tianqing is conducting 135 clinical trials, including 110 clinical trials of innovative drugs, accounting for 81%; in 2021, a total of 42 new projects have been established, of which 41 are innovative drugs, accounting for an absolute proportion
.
In terms of products, a number of innovative monoclonal antibodies, bispecific antibodies, and cell therapy products are under development, including CD20-CD3 bispecific antibodies, BCMA-CD3 bispecific antibodies, CD38 monoclonal antibodies, and CD38-CD3 bispecific antibodies, For cell therapy products, etc.
, from the perspective of therapeutic targets, Chia Tai Tianqing Pharmaceutical has deployed a number of popular targets such as PD-(L)1, ALK, EGFR, PI3K, CDK4/6, MEK, c-Met, and DPP4
.
In terms of class 1 new drugs, the PD-1 monoclonal antibody Piamprimab, which has cooperated with Kangfang Biotechnology, has been approved for marketing.
Head and neck squamous cell carcinoma, non-small cell lung cancer, biliary tract cancer and other indications have entered phase III clinical trials .
.
Especially in the field of ADC drugs and antibody drugs, as more companies increase their weight, they are facing a more complex competitive situation
.
In recent years, ADC drugs have entered the outbreak stage.
A total of 14 ADC drugs have been approved for marketing in the world, and 4 have been approved in China .
In 2021, the global ADC drug market size will exceed USD 5 billion .
According to an article published by Nature Reviews, the market size of the first 10 ADC drugs to market is expected to exceed $16.
4 billion by 2026 .
According to the analysis of CITIC Securities, assuming that the first 10 ADC drugs to be marketed account for 40% of the market share, it is predicted that the global sales will reach 41 billion US dollars .
In the face of considerable market prospects, ADC drugs have set off a research and development boom in the world.
There are 408 ADC drugs under research in the world, and most of them are in the early clinical stage .
In terms of multinational pharmaceutical companies, in addition to Roche and AstraZeneca, which have already entered the market, Johnson & Johnson and Eli Lilly have also reached cooperation with Mersana and ImmunoGen respectively this year, and have invested more than 1 billion US dollars to enter the ADC track .
The late-stage pipeline products of domestic pharmaceutical companies ADC drugs are mainly developed by foreign companies and joint development, and the research targets are HER2 and TROP2 .
There are a total of 74 ADC drugs in different research and development stages in China .
Among them, the clinical phase I accounted for the highest proportion.
This part of the drug is mainly developed by domestic companies.
Representative companies include Rongchang Bio, Lepu Bio, Doxi Bio, Kelun Pharmaceutical, Hengrui Medicine, etc.
Antibody drugs, as the most popular category in the global pharmaceutical R&D pipeline, have attracted much market attention .
A large number of popular targets are sought after by enterprises, and targets such as PD-1/PD-L1, VEGF, TNFα, EGFR, HER2, CD20, CGRP/CGRPR, PCSK9, CDK4/6 and other targets are being developed .
According to data from Minet.
com, from the perspective of the number and varieties of antibody drugs that have been marketed around the world, as of the end of 2021, the US FDA has approved a total of 108 antibody drugs, and the global antibody drug market is rising
.
In 2020, the global antibody drug market sales will reach 176 billion US dollars, a year-on-year increase of 5.
88%, and will exceed 180 billion US dollars in 2021
.
There are more than 50 bioengineered antibody drugs on the market in China, and the domestic antibody drug market has risen to more than 20 billion yuan
.
The TOP5 varieties are bevacizumab, trastuzumab, rituximab, pertuzumab and cetuximab
.
From the perspective of the industry, due to the high risk, large investment and long cycle of innovative drug research and development, as more large pharmaceutical companies join the battle, the pipeline and business of innovative drugs should still be focused, and the gold content and competition barriers of technology should be improved.
Seek new opportunities below .
I grew up in the south of China.
My past was in a small town of less than 20,000 people.
My memories grew like corrugated grass on those low roofs, as well as the slate-paved streets and the jutting out.
Households, a river running through the town, and of course small alleys jutting out from both sides of the street like branches
Later, I came to the north and settled in Beijing, the largest city in China
.
When I first came to Beijing, high-rise buildings were being built everywhere in Beijing, roads were being built everywhere, Beijing was like a huge construction site, and the shouts of construction workers and the roar of machines continued day and night
I read this sentence when I was young: "I walk on the streets of Beijing in autumn.
.
.
" This sentence made me excited because I didn't know what it would be like to walk on the streets of Beijing in autumn
It should be said that I like Beijing, even as a construction site, I also like Beijing.
My addiction to miscellaneous things makes Beijing look vibrant
.
This is because the Kaza in Beijing does not affect my inner peace
Through this new cooperation, Huadong Medicine will introduce a variety of ADC innovative products
I grew up in the south of China.
My past was in a small town of less than 20,000 people.
My memories grew like corrugated grass on those low roofs, as well as the slate-paved streets and the jutting out.
Households, a river running through the town, and of course small alleys jutting out from both sides of the street like branches
Later, I came to the north and settled in Beijing, the largest city in China
.
When I first came to Beijing, high-rise buildings were being built everywhere in Beijing, roads were being built everywhere, Beijing was like a huge construction site, and the shouts of construction workers and the roar of machines continued day and night
I read this sentence when I was young: "I walk on the streets of Beijing in autumn.
.
.
" This sentence made me excited because I didn't know what it would be like to walk on the streets of Beijing in autumn
It should be said that I like Beijing, even as a construction site, I also like Beijing.
My addiction to miscellaneous things makes Beijing look vibrant
.
This is because the Kaza in Beijing does not affect my inner peace
.
When the night comes, or in the daytime, I am walking on the street alone, thinking about my own affairs, and countless people around me are walking past and coming, but they don't even know me
.
I thought quietly about my own business, and although I was walking in the crowd, no one would bother me
.
I felt like I was walking in someone else's city
.
The coordinated development of anti-infection, respiratory system and other fields” has changed
.
By cooperating with Biositu, we will develop fully human antibody drugs targeting the targets jointly selected by both parties, and rapidly advance the drug research and development of the selected targets .
In cooperation with Jingtai Technology, the two parties will jointly develop new small molecule drugs for difficult targets for the treatment of malignant tumors .
In addition to R&D cooperation and commercialization cooperation, Chia Tai Tianqing and Yiyi Bio have reached a strategic cooperation in China on F-627 (US trade name Ryzneuta).
F-627 is based on Fc fusion protein technology and expressed by CHO cells.
rhG-CSF Dimer for the prevention and treatment of neutropenia in tumor patients during chemotherapy .
Yiyi Bio will receive up to 210 million yuan in down payments and milestone payments, as well as double-digit tiered royalties on net sales .
F-627 is an international multi-center clinical phase III drug and is currently undergoing BLA review by the US FDA .
In 2021, Chia Tai Tianqing invested 2.
74 billion yuan in R&D and obtained 13 new product registration approvals .
According to data from Minet.
com, Chia Tai Tianqing Pharmaceutical has 66 new drugs (excluding new indications for new drugs that have been listed) that are in the clinical application stage and above, of which 52 are Category 1 new drugs .
Among them, 20 biological drugs are in the approved clinical stage and above, and 9 of them are in the phase III clinical stage and above .
At the end of January, Chia Tai Tianqing Pharmaceutical's adalimumab injection was approved for marketing, which is the first approved biosimilar drug of Chia Tai Tianqing .
Currently, CP Tianqing is conducting 135 clinical trials, including 110 clinical trials of innovative drugs, accounting for 81%; in 2021, a total of 42 new projects have been established, of which 41 are innovative drugs, accounting for an absolute proportion
.
In terms of products, a number of innovative monoclonal antibodies, bispecific antibodies, and cell therapy products are under development, including CD20-CD3 bispecific antibodies, BCMA-CD3 bispecific antibodies, CD38 monoclonal antibodies, and CD38-CD3 bispecific antibodies, For cell therapy products, etc.
, from the perspective of therapeutic targets, Chia Tai Tianqing Pharmaceutical has deployed a number of popular targets such as PD-(L)1, ALK, EGFR, PI3K, CDK4/6, MEK, c-Met, and DPP4
.
In terms of class 1 new drugs, the PD-1 monoclonal antibody Piamprimab, which has cooperated with Kangfang Biotechnology, has been approved for marketing.
Head and neck squamous cell carcinoma, non-small cell lung cancer, biliary tract cancer and other indications have entered phase III clinical trials .
Innovative drug pipeline needs to be focused
I grew up in the south of China.
My past was in a small town of less than 20,000 people.
My memories grew like corrugated grass on those low roofs, as well as the slate-paved streets and the jutting out.
Households, a river running through the town, and of course small alleys jutting out from both sides of the street like branches
.
When I walk in the alley, the low buildings will look a lot taller because the alley is too narrow
.
Later, I came to the north and settled in Beijing, the largest city in China
.
When I first came to Beijing, high-rise buildings were being built everywhere in Beijing, roads were being built everywhere, Beijing was like a huge construction site, and the shouts of construction workers and the roar of machines continued day and night
.
I read this sentence when I was young: "I walk on the streets of Beijing in autumn.
.
.
" This sentence made me excited because I didn't know what it would be like to walk on the streets of Beijing in autumn
.
When I first came to Beijing, it happened to be autumn.
I was walking on the streets of Beijing.
I saw wide streets, high-rise buildings, and endless crowds of vehicles.
I thought to myself: this is walking on the streets of Beijing
.
It should be said that I like Beijing, even as a construction site, I also like Beijing.
My addiction to miscellaneous things makes Beijing look vibrant
.
This is because the Kaza in Beijing does not affect my inner peace
.
When the night comes, or in the daytime, I am walking on the street alone, thinking about my own affairs, and countless people around me are walking past and coming, but they don't even know me
.
I thought quietly about my own business, and although I was walking in the crowd, no one would bother me
.
I felt like I was walking in someone else's city
.
.
Especially in the field of ADC drugs and antibody drugs, as more companies increase their weight, they are facing a more complex competitive situation
.
In recent years, ADC drugs have entered the outbreak stage.
A total of 14 ADC drugs have been approved for marketing in the world, and 4 have been approved in China .
In 2021, the global ADC drug market size will exceed USD 5 billion .
According to an article published by Nature Reviews, the market size of the first 10 ADC drugs to market is expected to exceed $16.
4 billion by 2026 .
According to the analysis of CITIC Securities, assuming that the first 10 ADC drugs to be marketed account for 40% of the market share, it is predicted that the global sales will reach 41 billion US dollars .
In the face of considerable market prospects, ADC drugs have set off a research and development boom in the world.
There are 408 ADC drugs under research in the world, and most of them are in the early clinical stage .
In terms of multinational pharmaceutical companies, in addition to Roche and AstraZeneca, which have already entered the market, Johnson & Johnson and Eli Lilly have also reached cooperation with Mersana and ImmunoGen respectively this year, and have invested more than 1 billion US dollars to enter the ADC track .
The late-stage pipeline products of domestic pharmaceutical companies ADC drugs are mainly developed by foreign companies and joint development, and the research targets are HER2 and TROP2 .
There are a total of 74 ADC drugs in different research and development stages in China .
Among them, the clinical phase I accounted for the highest proportion.
This part of the drug is mainly developed by domestic companies.
Representative companies include Rongchang Bio, Lepu Bio, Doxi Bio, Kelun Pharmaceutical, Hengrui Medicine, etc.
Antibody drugs, as the most popular category in the global pharmaceutical R&D pipeline, have attracted much market attention .
A large number of popular targets are sought after by enterprises, and targets such as PD-1/PD-L1, VEGF, TNFα, EGFR, HER2, CD20, CGRP/CGRPR, PCSK9, CDK4/6 and other targets are being developed .
According to data from Minet.
com, from the perspective of the number and varieties of antibody drugs that have been marketed around the world, as of the end of 2021, the US FDA has approved a total of 108 antibody drugs, and the global antibody drug market is rising
.
In 2020, the global antibody drug market sales will reach 176 billion US dollars, a year-on-year increase of 5.
88%, and will exceed 180 billion US dollars in 2021
.
There are more than 50 bioengineered antibody drugs on the market in China, and the domestic antibody drug market has risen to more than 20 billion yuan
.
The TOP5 varieties are bevacizumab, trastuzumab, rituximab, pertuzumab and cetuximab
.
From the perspective of the industry, due to the high risk, large investment and long cycle of innovative drug research and development, as more large pharmaceutical companies join the battle, the pipeline and business of innovative drugs should still be focused, and the gold content and competition barriers of technology should be improved.
Seek new opportunities below .
